Navigating the New World of AML Treatment

Register now to interact with peers while gaining expert insight on the optimal treatment of AML in this interactive, case-based 1-hour live meeting. After the meeting, download the associated slideset for use in your clinic.


Managing Newly Diagnosed AML: Treatment Considerations to Personalize Care
Clinical case vignettes will explore:

  • Balancing the risks and benefits of available induction, consolidation, and maintenance treatment options
  • Options for elderly vs fit patients
    • CPX-351
  • Clinical challenges of AML in the elderly population
  • Key cytogenetic and molecular factors to consider
    • FLT3 and midostaurin
  • The importance of an individualized treatment approach

Relapsed/Refractory AML: Considerations and Challenges
Clinical case vignettes will explore:

  • Checklist of variables to consider in selecting treatment
    • Impact of age
    • Duration of first CR
    • Cytogenetics
    • Molecular abnormalities
    • Immunophenotypic changes on outcomes
    • Patient preferences
  • Examples of choosing therapy for R/R AML based on variations of the above factors

Integrating Emerging Targeted Therapies in AML Treatment Selection
New data/ongoing clinical trials and the implications on the future AML treatment landscape. Classes include:

  • FLT3 TKIs (midostaurin, quizartinib, sorafenib, gilteritinib)
  • Topoisomerase II inhibitor (vosaroxin)
  • IDH inhibitors (enasidenib and ivosidenib)
  • SMO inhibitor (glasdegib)
  • BCL-2 inhibitor (venetoclax)
  • PLK-1 inhibitor (volasertib)
  • Monoclonal antibodies and conjugates
    • Anti-CD33 antibody–drug conjugates (gemtuzumab ozogamicin, vadastuximab talirine)
    • Anti-CD123 antibodies (JNJ-56022473, KHK2823)
    • Anti-CD25 antibody (ADCT-301)
    • Anti-CD37 antibody (AGS67E)
  • Cytotoxic agents (azacitidine, clofarabine, sapacitabine)
  • Additional drug classes

Conclusions and Question and Answer Session


Date / Time
Event Details


Gary Schiller, MD

Director, Hematological Malignancy/Stem Cell Transplantation
Professor, Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eunice Wang, MD

Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Goal Statement
The goal of this activity is to improve participants’ competence and performance in applying the latest practice-changing developments to the clinical care of patients with acute myeloid leukemia.

Target Audience 
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with acute myeloid leukemia.

Learning Objectives 

  • Evaluate the clinical data on prognostic or therapeutically relevant molecular (genetic, epigenetic, protein) features or aberrations in AML and describe their clinical importance in terms of risk prediction, diagnosis, and prognosis
  • Plan evidence-based therapeutic strategies for patients with AML, including elderly patients, those with relapsed/refractory disease, or patients with poor-risk cytogenetics
  • Discuss emerging safety and efficacy data and ongoing clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents for patients with AML who may not benefit from standard therapy
  • Identify patients with AML who may benefit from enrollment on clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents


Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-740-L01-P.

Type of Activity

Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.